Nanexa Shares Surge 150% After Novo Nordisk Licensing Deal
The agreement gives Novo Nordisk rights to use Nanexa’s technology across up to five injectable-drug programs, with potential upfront, milestone and royalty payments.
Swedish drug-delivery company Nanexa saw its shares surge more than 150% at Friday’s open after signing a licensing agreement with Novo Nordisk worth up to $1.33 billion, linking the microcap stock to the expanding market for obesity treatments.
The agreement gives Novo Nordisk exclusive rights to use Nanexa’s PharmaShell technology in up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. The programs will focus on injectable medicines that may be administered monthly or quarterly.
Nanexa is eligible for an upfront payment of about $700 million, along with additional payments tied to development and regulatory milestones. The agreement also includes low single-digit royalties on future product sales.
Nanexa posted approximately $3.89 million in revenue for 2025, up 48.4% from the previous year.
PharmaShell uses an ultra-thin inorganic coating on drug particles to control how quickly medicines are released, supporting longer intervals between injections.
